An interventional study of Potassium Chloride and Potassium Citrate in Renal Insufficiency, Chronic, Potassium Depletion and Hypertension, sponsored by Erasmus Medical Center. Active, not recruiting at 4 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment
The current high-sodium, low-potassium diet contributes to the high prevalence of high blood pressure (hypertension). Indeed, the anti-hypertensive effects of potassium supplementation are well-established. Hypertension is even more prevalent and resistant in patients with chronic kidney disease (CKD) and contributes to further decline in kidney function. Four recent epidemiological studies (published 2014 - 2016) showed that higher dietary potassium intake was associated with better renal outcomes. All studies recommended an intervention study with potassium supplementation in patients with CKD, but this has not been performed. The aim of this study is to study the renoprotective effect of potassium supplementation in patients with CKD (stage 3b or 4, i.e. estimated glomerular filtration rate [eGFR] 15 - 45 ml/min/1.73 m2).
3,090 studies on the registry are indexed under Renal Insufficiency, Chronic; 698 are open to participants now.
This study's planned enrollment of 532 is above the median of 73 across 2,157 interventional studies indexed under Renal Insufficiency, Chronic.
Browse Renal Insufficiency, Chronic studies →Erasmus Medical Center is the lead sponsor of 478 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Dietary Supplement: Placebo
Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
Dietary Supplement: Potassium Chloride
Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
Dietary Supplement: Potassium Citrate
Two potassium supplements with varying anions.
Potassium Citrate
Placebo
Difference in estimated glomerular filtration rate (eGFR)
Time frame: Two years
≥ 30% decrease in eGFR
Time frame: Two years
Slope analysis (change in eGFR in ml/min/1.73 m2/year)
Time frame: Two years
Doubling in serum creatinine or kidney failure (CKD stage 5 or start of kidney replacement therapy)
Time frame: Two years
Progression to next CKD or albuminuria class
Time frame: Two years
Ambulatory (24-hour) blood pressure
Time frame: Two years
Spot urine albumin to creatinine ratio (UACR)
Time frame: Two years
Cardiovascular event
Coronary heart disease death, fatal myocardial infarction, fatal stroke and other cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, unstable angina, resuscitated cardiac arrest
Time frame: Two years
All-cause mortality
Time frame: Two years
Incidence of hyperkalemia
Time frame: Two years
NT-pro-BNP
Volume marker 1
Time frame: Two years
Bioimpedance measures
Volume marker 2
Time frame: Two years
Pulse-wave velocity
Cardiovascular marker 1
Time frame: Two years
High-sensitive CRP
Cardiovascular marker 2
Time frame: Two years
Effects of 2-week KCl supplementation on plasma potassium (mmol/l)
Run-in outcome 1
Time frame: Two weeks
Incidence of Hyperkalemia after 2-week KCl supplementation
Run-in outcome 2
Time frame: Two weeks
Effects of 2-week KCl supplementation on office blood pressure (mmHg)
Run-in outcome 3
Time frame: Two weeks
Plan to share: Undecided
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Potassium Chloride · Potassium Citrate
Renal Insufficiency, Chronic →